Porovnať metódy

	Index kvality života v dermatológii (DLQI)	EORTC QLQ-C30	Dotazník Parkinsonovej choroby – 39 (PDQ-39)
Odbor	Zdravotné výsledky	Zdravotné výsledky	Zdravotné výsledky
Rodina	Process / pipeline	Process / pipeline	Process / pipeline
Rok vzniku	1994	1993	1997
Tvorca	Andrew Y. Finlay and Gul K. Khan	Nico Aaronson et al.	Crispin Jenkinson et al.
Typ	Self-report quality of life questionnaire	Self-report quality of life questionnaire	Self-report quality of life questionnaire
Pôvodný zdroj	Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216.	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357.
Ďalšie názvy	DLQI, Finlay Index, Dermatology Quality of Life	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	PDQ-39, Parkinson's Disease Questionnaire, PDQ
Príbuzné	3	5	4
Zhrnutie	The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice. Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders.